Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s rezpegaldesleukin in atopic dermatitis – AD – Phase 2B readout in June. The risk/benefit profile on the stock is favorable considering that Nektar is trading at negative enterprise value and at a deep discount compared to peers with Phase 2 AD assets, the analyst tells investors in a research note. Phase 1B data was promising, and rezpeg’s differentiated profile could deliver meaningful benefits in an expanding market, Oppenheimer added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar upgraded to Outperform from Perform at Oppenheimer
- Nektar up 12% to 91c after Oppenheimer upgrade with $6 target
- Nektar Therapeutics: Poised for Growth with Promising Rezpeg Study and Market Potential
- Promising Pipeline and Strategic Positioning: Julian Harrison’s Buy Rating on Nektar Therapeutics
- Nektar Therapeutics Reports 2024 Financial Progress
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue